Navigation Links
Treating gum disease improves vascular health in Indigenous Australians: Study
Date:6/26/2014

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

The study findings may be of particular importance to Aboriginal Australians, who in general have poorer oral health and higher rates of cardiovascular disease.

Published in the latest issue of Hypertension, the study reports a significant decline in thickening of the wall of the carotid artery a year after a single session of gum treatment.

"The study shows that non-surgical periodontal therapy significantly reduced the progression of thickening of the carotid artery over a one-year period," says study co-author, University of Sydney vascular disease expert Dr Michael Skilton.

"The magnitude of the reduction in thickening of the carotid artery in the treatment group, relative to the control group, is similar to what has been observed in other clinical trials in high risk populations.

"The effect is comparable to a 30 per cent fall in low-density lipoprotein cholesterol commonly referred to as 'bad' cholesterol which is associated with a decreased risk of heart disease.

"It's also equivalent to the effects of reversing four years of aging, 8 kg/m2 lower body mass index, or 25 mm Hg lower systolic blood pressure."

The study was prompted by conjecture about the causative relationship between periodontal (gum) disease and atherosclerotic vascular disease and is among the first using a randomised trial to investigate a periodontal intervention on atherosclerotic disease.

Periodontal disease is an inflammatory disease affecting the soft and hard structures that support the teeth. In its early stage, the gums become swollen and red due to inflammation, which is the body's natural response to the presence of harmful bacteria.

In the more serious form of periodontal disease (periodontitis), the gums pull away from the tooth and supporting gum tissues are destroyed. Bone can be lost, and the teeth may loosen or eventually fall out.

Atherosclerosis is the most common cause of heart attacks, strokes, and peripheral vascular disease collectively known as 'cardiovascular disease'. It usually causes no symptoms until middle or older age but as narrowing and hardening of the arteries accelerates, they choke blood flow, causing pain and other serious cardiovascular complications.

Despite reducing thickening of the carotid artery, the study found no effect of periodontal therapy on arterial stiffness another pre-clinical marker of atherosclerotic vascular disease and risk factor for cardiovascular disease.

"Future studies may tell us whether a more intensive approach to periodontal therapy, including regular periodontal maintenance schedules, can produce more marked improvements in vascular structure," Dr Skilton says.

"The findings indicate that periodontal therapy has a systemic impact beyond treating gum disease.

"If further studies can confirm our report the treatment of periodontal disease may become reducing means by which to reduce the risk of cardiovascular disease, especially in high risk populations such as Indigenous Australians."


'/>"/>

Contact: Dan Gaffney
daniel.gaffney@sydney.edu.au
61-411-156-015
University of Sydney
Source:Eurekalert

Related medicine news :

1. Methadone programs can be key in educating, treating HCV patients
2. Researchers propose treating prison population to fight US hepatitis C epidemic
3. Extended-release medication offers promise for treating alcohol, opioid dependence
4. Widely used drug no more effective than FDA approved medication in treating epileptic seizures
5. Study unveils new approach to treating brittle bone disease
6. Vibrating capsule shows promising results in treating chronic constipation
7. Treating depression in PD patients: New research
8. CU researchers discover target for treating dengue fever
9. New study confirms benefits of treating heart attack patients with a cheap drug
10. Scientists find potential target for treating mitochondrial disorders
11. Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... , ... With the FCPX LUT: Summer pack from Pixel Film ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. ... By manipulating each pixel, LUT's can change each color range differently, it gives the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, hosted ... feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on Friday, ... on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - people ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy ... Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. ... dystrophy, ALS and related diseases that severely limit strength and mobility. , ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... --  Bernstein Liebhard LLP today announced that a securities ... Court for the District of Arizona ... persons or entities who purchased common shares of Insys Therapeutics ... March 3, 2015 through January 25, 2016 (the "Class Period").  ... violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 4, 2016  Montoya Love is recognized by Continental ... of Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager ... Manufacturing and selling a broad ... provides healthcare institutions, clinical laboratories and life science ... across the globe. ...
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
Breaking Medicine Technology: